Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Kissei Pharmaceutical Co ( (JP:4547) ) has issued an announcement.
Kissei Pharmaceutical Co. reported its consolidated financial results for the six months ending September 30, 2025, showing a 7.9% increase in net sales compared to the previous year, despite operating and ordinary profits being negative. The company experienced a significant rise in profit attributable to owners of the parent, indicating a 48.3% increase. This financial performance reflects a strategic shift and potential recovery in market positioning, with implications for stakeholders as the company revises its financial forecasts for the fiscal year ending March 31, 2026.
The most recent analyst rating on (JP:4547) stock is a Hold with a Yen4473.00 price target. To see the full list of analyst forecasts on Kissei Pharmaceutical Co stock, see the JP:4547 Stock Forecast page.
More about Kissei Pharmaceutical Co
Kissei Pharmaceutical Co., Ltd. is a company listed on the Tokyo Stock Exchange, primarily engaged in the pharmaceutical industry. The company focuses on the development and sale of pharmaceutical products, with a significant emphasis on innovative treatments and therapies.
Average Trading Volume: 62,854
Technical Sentiment Signal: Buy
Current Market Cap: Yen164.4B
See more insights into 4547 stock on TipRanks’ Stock Analysis page.